Actually, US sales of Gilenya have nearly reached a plateau, rising only 6% YoY from $170M to $181M (http://www.novartis.com/downloads/investors/financial-results/quarterly-results/2012-07-interim-financial-report.pdf page 61); it’s the rapid growth internationally that has turned Gilenya into a $1B+ blockbuster.